List view / Grid view
16 September 2024 | By Drug Target Review
The increasing use of AI in the life science field marks a pivotal point in history. Although AI is now an indispensable tool in drug discovery, promising to save vast amounts of time and money, there are still many hurdles scientists encounter. This webinar will explore these challenges and offer…
The expansion of Sino Biological and BioGeometry’s strategic partnership promises to accelerate drug discovery.
This study is the first to demonstrate that NSD2 is foundational to the earliest stage of prostate cancer development.
Microbeads enabled the precise release of signal molecules at any time or location within retinal organoids.
At AAIC 2024, AC Immune unveiled a new class of antibody drug conjugates, called morADC (Morphomer® antibody drug conjugate). In this Q&A, CEO of AC Immune, Andrea Pfeifer, discusses how morADC uses the capabilities of the company’s two discovery platforms to combine two highly selective molecules, resulting in drug candidates…
The publicly available Human Endometrial Cell Atlas could progress the development of therapeutics for endometriosis.
With increasingly rapid timelines for achieving IND-ready processes, a bottleneck has emerged in the provision of toxicology data to support INDs for new therapeutics and hence delivery of FIH studies, explains Alejandro Fernandez Martell and James Berrie from Lonza.
The study’s findings could contribute to future therapeutic strategies to prevent chronic kidney disease.
In this Q&A, Revolo Biotherapeutics’ CEO, Woody Bryan, discusses how ‘1104, the Company’s lead candidate for allergic diseases, shifts the immune system from a pro-inflammatory state to a homeostatic state, offering potential remission for allergic conditions. We delve into its unique mechanism of action, supported by preclinical and clinical findings.…
The mRNA vaccine candidate more effectively limited symptoms and disease duration in non-human primates.
Researchers found that HD can impair early brain development through defects associated with mitochondrial dysfunction.
NpG-D-PSMA has shown great potential for targeted alpha therapy to combat prostate cancer.
The findings could aid the design of more stable drugs and improve the understanding of diseases linked to peptide aggregation.
RENAISSANCE can quantify unknown intracellular metabolic states, including metabolic fluxes.
The nucleic acid drug, iSN04, could have applications for pathological angiogenesis involved in atherosclerosis, cancer, and retinopathy.
